Numinus Wellness (NUMI.T), a Canadian-based company focused on the development and delivery of innovative evidence-based psychedelic-assisted therapies, announced today that it had expanded its research capabilities into Arizona. The…
NUMI.T
Some positive action on psychedelic stocks in the last few days. As a technical analyst, there are good signs indicating a reversal is occurring. The downtrend is over, and…
Numinus Wellness (NUMI.T) has moved into the implementation part of their MDMA-assisted psychotherapy trial for post-traumatic stress disorder (PTSD) clinical trial by enrolling and dosing its first volunteer. Numinus…
Numinus Wellness (NUMI.T) research lab, Numinus Bioscience, received the nod from the Public Health Agency of Canada for their containment level 2 (CL2) pathogens and toxins license after the…
Numinus Wellness (NUMI.T) got the Health Canada nod to study ayahuasca and San Pedro at its research facility, Numinus Bioscience today. The license expansion works to boost NUMI’s profile…
We’re not out of the woods yet, but the major indices are turning green again and psychedelics, recently a relative investment pariah, are getting some love from investors. The…
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…
Another Psychedelics article, and once again I try to answer the question: is it time to buy the dips in Psychedelics. My views remain the same. In this market,…
$144.185M Market Capitalization Numinus Wellness Inc. (NUMI.T) announced today that it has completed key steps in preparation for enrollment at the Company’s clinics participating in a “multi-site open-label extension…
$140.123M Market Capitalization Numinus Wellness Inc. (NUMI.T) announced today that it has formally submitted its clinical trial application (CTA) to Health Canada for its Phase 1 study, HOPE, on…